Skip to content

David A Bender

6 papers in the library · 334 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Trends in the psychedelic renaissance: applying artificial intelligence to measure media portrayal of psychedelic drugs in the 21st century

BJPsych Open February 12, 2026 David A Bender, Holly Dunn, Amanda Pekau et al. 1 citation

Background The relationship between media portrayal of psychedelic drugs, scientific research and drug policy is an area of debate. Aims To apply artificial intelligence technology to measure trends in media sentiment towards the therapeutic potential of psychedelic drugs. Method Up to 300 of the most relevant articles from Google News searches for the term ‘psychedelics’ were sampled for each...

Provider perspectives on challenges in treatment during psychedelic therapy.

Psychopharmacology October 27, 2025 David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al.

Psychedelic treatments are considered to involve unique treatment challenges relative to other psychiatric interventions, though these are typically not explored in detail within clinical trial reports. To determine the types of challenges that providers encounter while administering psychedelic drugs in research settings and to assess provider opinions on safeguards that may be pursued to...

The Role of Touch in Psychedelic Therapy: Perspectives From a Survey of Practitioners in Research Settings.

American Journal of Psychotherapy May 6, 2025 David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al. 7 citations

Psychedelic therapies are promising new treatment options in psychiatry. Including the use of physical touch as part of treatment is an area of debate. This study aimed to characterize the viewpoints of practitioners on the use of touch in psychedelic therapy. An anonymous survey was distributed via e-mail to the contacts listed on ClinicalTrials.gov for trials of psilocybin and lysergic acid...

Psychological Support Approaches in Psychedelic Therapy: Results From a Survey of Psychedelic Practitioners.

The Journal of Clinical Psychiatry February 5, 2025 David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al. 3 citations

Objective: To assess the viewpoints of psychedelic practitioners in research settings on approaches to psychological support for psychedelic treatments. Methods: An anonymous survey was distributed via email to contacts listed on ClinicalTrials.gov for clinical trials of psilocybin and LSD, personal contacts of authors, and through snowball sampling. The survey included Likert type, multiple...

Psilocybin desynchronizes the human brain.

Nature August 1, 2024 Joshua S. Siegel, Subha Subramanian, Demetrius Perry et al. 241 citations

A single dose of psilocybin, a psychedelic that acutely causes distortions of space-time perception and ego dissolution, produces rapid and persistent therapeutic effects in human clinical trials1-4. In animal models, psilocybin induces neuroplasticity in cortex and hippocampus5-8. It remains unclear how human brain network changes relate to subjective and lasting effects of psychedelics. Here...

Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research

Psychopharmacology January 13, 2022 David A Bender, David J Hellerstein 82 citations

RationaleA broad reassessment of the potential benefits of psychedelic drugs has led to the initiation of multiple major clinical trials in an effort to advance their status to become FDA-approved medications, as well as local legislative efforts to legalize or decriminalize their use.ObjectivesTo use recently published data to assess potential risks and benefits of psychedelic drugs as...